endostar protein: Clinical Trials

89 trials of endostar protein, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 unknown, 16 completed, 4 not yet recruiting, 2 recruiting. 67 Phase 2, 11 Phase 3, 7 Phase 4, 5 Phase 1, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 267Unknown 46, Completed 13, Not yet recruiting 4, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 311Unknown 10, Completed 1
Phase 47Unknown 6, Completed 1
Phase 15Unknown 3, Completed 2
Not applicable2Unknown 2

Follow endostar protein: new trials by email Literature Review of endostar protein trials Research Report on endostar protein

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
Stereotactic Radiation Therapy, Envafolimab, Endostar - Non Small Cell Lung Cancer, Lung Neoplasms
Phase 2Not yet recruitingThe First People's Hospital of Lianyungang612026-10-012026-09-14
Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases
Recombinant Human Endostatin (Endostar) - Lung Cancer (Non-Small Cell), Radiation
Phase 2Not yet recruitingJiangmen Central Hospital492026-09-012026-10-01
Platinum-Free Regimen in Nasopharyngeal Carcinoma
Endostar (recombinant human endostatin injection) - Nasopharyngeal Cancinoma (NPC)
Phase 2Not yet recruitingZhejiang Cancer Hospital1452026-09-012026-08-31
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Toripalimab combined with Endostar - Melanoma of Skin, Acral Melanoma
Phase 2RecruitingFudan University582025-01-012025-05-11
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) - Osteosarcoma, Bone Cancer
Phase 1 / Phase 2CompletedShanghai 6th People's Hospital102024-12-032025-12-29
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5 - Non-small Cell Lung Cancer
Phase 2Not yet recruitingHenan Cancer Hospital842024-10-082024-10-01
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar) - Unresectable Non-small Cell Lung Cancer
Phase 2RecruitingHua Zhang362024-08-272025-07-15
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Envafolimab Injection, Endostar - Gastrointestinal Neoplasms
Phase 2UnknownNanjing First Hospital, Nanjing Medical University162024-02-212024-03-08
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Endostar and Envafolimab - Nasopharyngeal Carcinoma
Phase 2Active not recruitingZhejiang Cancer Hospital402023-10-242026-10-06
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV). - Lung Squamous Cell Carcinoma
Phase 4UnknownXuzhou Medical University302023-06-012023-03-24
Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
cis-platinum, radiation, Envafolimab Injection - Cervical Cancer
UnknownPeking University Third Hospital302023-05-162023-05-30
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Envafolimab plus Endostar and S-1, Envafolimab plus Endostar, Envafolimab plus S-1 - Carcinoma, Non-Small-Cell Lung
Phase 2UnknownAnhui Chest Hospital452022-09-182022-09-07
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
Envafolimab, Endostar, Nab paclitaxel - Advanced Pancreatic Cancer
Phase 2UnknownThe Affiliated Hospital of Xuzhou Medical University202022-04-012022-03-28
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
Envafolimab, Endostar - Lung Neoplasms
Phase 2UnknownThe First People's Hospital of Lianyungang402022-03-012023-06-22
PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy
Endostar, use the vein pump to pump drugs, combination therapy - Advanced or Metastatic NSCLC
Phase 1UnknownJiangsu Simcere Pharmaceutical Co., Ltd.242021-07-302021-06-30
Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma
Endostar - Nasopharyngeal Carcinoma
Phase 2UnknownJiangxi Provincial Cancer Hospital302021-07-282022-01-04
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial
Recombinant human endostatin (Endostar) - Non-Small-Cell Lung Cancer
Phase 2UnknownQianfoshan Hospital1002021-02-012022-10-12
Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
Recombinant human endostatin (Endostar), Thoracic irradiation of 50 Gy with 3DCRT or IMRT - Lung Cancer
Phase 4UnknownShanghai Chest Hospital972020-12-012020-11-03
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment
Endostar (recombinant human endostatin injection), Chemotherapy AI - Other Disorders of Soft Tissues
Phase 2UnknownYong Chen2102020-09-012021-01-07
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Toripalimab, chemotherapy in combination with Endostar - Mucosal Melanoma
Phase 2UnknownFudan University312020-06-202020-07-15

Showing 20 of 89. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (22)  ·  Lung Neoplasms (8)  ·  Nasopharyngeal Carcinoma (8)  ·  Colorectal Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Esophageal Squamous Cell Carcinoma (3)  ·  Melanoma (3)  ·  Uterine Cervical Neoplasms (3)  ·  Esophageal Neoplasms (2)  ·  Lymphoma, T-Cell (2)  ·  Lymphoma, T-Cell, Peripheral (2)  ·  Nasopharyngeal Neoplasms (2)  ·  Osteosarcoma (2)  ·  Sarcoma (2)  ·  Adenocarcinoma of Lung (1)

Sponsors

Fudan University (8)  ·  Zhejiang Cancer Hospital (7)  ·  Jiangsu Simcere Pharmaceutical Co., Ltd. (6)  ·  Simcere Pharmaceutical Co., Ltd (4)  ·  First Affiliated Hospital of Guangxi Medical University (3)  ·  Nanjing NingQi Medicine Science and Technology Co., Ltd. (3)  ·  Peking University Third Hospital (3)  ·  Tianjin Medical University Cancer Institute and Hospital (3)  ·  Peking University Cancer Hospital & Institute (2)  ·  Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd (2)  ·  Shanghai Jiao Tong University School of Medicine (2)  ·  Sun Yat-sen University (2)  ·  The First People's Hospital of Lianyungang (2)  ·  Xinqiao Hospital of Chongqing (2)  ·  Zhejiang University (2)

Countries

China (78)

Top investigators

Xiaodong Jiang, MD (2)  ·  Bin Li (1)  ·  Changgui Wu, MD, PHD (1)  ·  Chunmeng Wang, Dr. (1)  ·  Daiyuan Ma, M.D (1)  ·  Degan Lu, professor (1)  ·  Dong Wang, PH.D (1)  ·  Fei Han, M.D., Ph.D. (1)  ·  Feng Shen, M.D. (1)  ·  Gu Yanhong, PI (1)  ·  Guo Jun, PI (1)  ·  Guoliang Jiang, MD (1)  ·  Hanmei Lou, PHD (1)  ·  Hong-Tao Li, Dr. (1)

Results publications

PMID 10640954, PMID 11212235, PMID 15172975, PMID 15746043, PMID 15752890, PMID 15920746, PMID 16012180, PMID 16139912, PMID 16807466, PMID 19564532, PMID 19692680, PMID 21108883, PMID 22099051, PMID 22209574, PMID 22496834, PMID 22537906, PMID 22562140, PMID 23670576, PMID 25198661, PMID 25244494, PMID 25497558, PMID 26434908, PMID 27067521, PMID 27566586, PMID 30773184, PMID 35380726, PMID 38700579, PMID 41014160, PMID 41049580